OBI Pharma, Inc. (TPEX:4174)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
27.90
-0.15 (-0.53%)
Jun 18, 2026, 1:30 PM CST
Market Cap3.67B -62.6%
Revenue (ttm)49.68M -26.9%
Net Income-1.98B
EPS-15.78
Shares Out 131.58M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume190,490
Open28.10
Previous Close28.05
Day's Range27.85 - 28.30
52-Week Range27.60 - 73.20
Beta0.08
AnalystsHold
Price Target296.00 (+960.93%)
Earnings DateAug 12, 2026

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment o... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4174
Full Company Profile

Financial Performance

In 2025, OBI Pharma's revenue was 58.58 million, a decrease of -6.55% compared to the previous year's 62.68 million. Losses were -2.05 billion, -11.13% less than in 2024.

Financial Statements